Renown Health is excited to announce participation in our first rheumatology clinical trial, marking a significant milestone in our commitment to advancing medical research and improving patient care. The study, led by rheumatologist and site-level Principal Investigator Dr. Kennedy Ukadike, focuses on evaluating the safety and efficacy of the experimental drug litifilimab in patients with systemic lupus erythematosus (SLE).
This groundbreaking study is titled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care." The study will focus on participants who have the disease and are already taking standard medications. The main goal of the study is to learn about the effect litifilimab has on lowering the activity of the disease. Participants will be randomized to receive either a high or low dose of the drug, or a placebo, with the treatment period lasting 52 weeks and a follow-up safety period of up to 24 weeks.
Dr. Kennedy Ukadike shared his enthusiasm for the study: “This clinical trial represents a pivotal step in our efforts to better understand and treat systemic lupus erythematosus. We are hopeful that the findings will lead to more effective therapies and improved quality of life for our patients.
“Launching our first rheumatology study is a testament to Renown’s dedication to pioneering research and delivering cutting-edge treatments to our community. This initiative not only enhances our research capabilities but also brings hope to patients and families affected by SLE,” said Kristen Gurnea, the Director of Clinical Research at Renown Health.
Renown Health invites patients who are interested in joining this important study or learning about other clinical trial opportunities available to you to contact the Renown Office of Clinical Research (OCR) at Renown-CRD@renown.org or 775-982-3646.
To contribute to Renown’s research initiatives, visit this link and select Renown Clinical Research.
